Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Molecular Partners ( (MOLN) ).
On March 23, 2026, Molecular Partners published its invitation to the 2026 Annual General Meeting, scheduled for April 14, 2026 in Schlieren, Switzerland, and proposed industry veteran Clare Fisher for election to the Board of Directors. The company also confirmed that long-standing board member Steven H. Holtzman, who helped steer key partnerships, listings and the COVID program over 12 years, will not stand for re‑election, marking a significant refresh in governance as the biotech advances its DARPin pipeline.
The board highlighted Fisher’s long track record in global business development, M&A and strategy across biotech and pharma, signaling a continued emphasis on dealmaking and portfolio growth. Alongside the board changes, Molecular Partners outlined its 2026 financial calendar, giving investors visibility on upcoming interim statements and half-year results as the company progresses multiple oncology programs and strategic collaborations.
The most recent analyst rating on (MOLN) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.
Spark’s Take on MOLN Stock
According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.
The score is weighed down primarily by collapsing revenue and persistent cash burn (weak financial performance), with additional pressure from negative technical momentum (below key moving averages with negative MACD). Valuation is also constrained by losses (negative P/E) and no dividend support.
To see Spark’s full report on MOLN stock, click here.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company focused on developing DARPin therapeutics, a novel class of custom-built protein drugs designed to tackle medical challenges that are hard to address with conventional modalities. The company is advancing proprietary oncology programs, including targeted radiopharmaceuticals and next‑generation immune cell engagers, and also runs partnered projects with major pharma and academic institutions, operating from hubs in Zurich, Switzerland, and Concord, Mass., U.S.
Average Trading Volume: 4,586
Technical Sentiment Signal: Sell
Current Market Cap: $164M
Learn more about MOLN stock on TipRanks’ Stock Analysis page.